[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 38 of about 38
1. Talbot SM, Taub RN, Keohan ML, Edwards N, Galantowicz ME, Schulman LL: Combined heart and lung transplantation for unresectable primary cardiac sarcoma. J Thorac Cardiovasc Surg; 2002 Dec;124(6):1145-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From 1996 through 1999, we performed combined heart and lung resection followed by en bloc heart and bilateral lung transplantation in 4 patients (2 men and 2 women): 2 with inoperable pulmonary arterial sarcoma and 2 with left atrial sarcoma extending into the pulmonary vein.
  • RESULTS: Median age at diagnosis was 39 years (range 37-45 years).
  • All 4 patients were given chemotherapy before transplantation: doxorubicin and ifosfamide in 2 cases, and doxorubicin, ifosfamide, mesna, and dacarbazine in 2 cases.
  • CONCLUSIONS: Combined heart and lung transplantation is a technically feasible treatment for highly selected patients with localized advanced primary cardiac sarcomas.
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Female. Humans. Male. Neoplasm Recurrence, Local. Pulmonary Artery. Vascular Neoplasms / drug therapy. Vascular Neoplasms / mortality. Vascular Neoplasms / surgery

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12447180.001).
  • [ISSN] 0022-5223
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


2. Oda Y, Takada R, Koitabashi K, Kurasawa T, Inoue T, Suzuki H, Kawai S, Aoki K, Ohmiya K: Isolated cardiac metastasis from sacral chordoma. Jpn Circ J; 2000 Aug;64(8):627-30
Genetic Alliance. consumer health - Chordoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A match between the biopsy specimen and tissue removed 4 years earlier resulted in the diagnosis of a cardiac metastasis from a chordoma.
  • Immunohistochemical staining was also useful in establishing the diagnosis.
  • To alleviate the right ventricular outflow obstruction, a palliative operation was planned, resecting the tumor and performing a right ventriculoplasty, which was cancelled due to the extent of infiltration of the tumor, and instead a right atrium to pulmonary artery shunt was attempted using a vascular prosthesis, only to fail due to an inability to maintain blood flow through the prosthesis.
  • Presently there are no definitive treatment options available, and some palliative chemotherapy is being performed.
  • [MeSH-minor] Antigens, Neoplasm / metabolism. Female. Humans. Immunohistochemistry. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Jpn Circ J 2000 Sep;64(9):740. Kawai, Y [corrected to Kawai, S]
  • (PMID = 10952163.001).
  • [ISSN] 0047-1828
  • [Journal-full-title] Japanese circulation journal
  • [ISO-abbreviation] Jpn. Circ. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] AUSTRALIA
  • [Chemical-registry-number] 0 / Antigens, Neoplasm
  •  go-up   go-down


3. Bakaeen FG, Jaroszewski DE, Rice DC, Walsh GL, Vaporciyan AA, Swisher SS, Benjamin R, Blackmon S, Reardon MJ: Outcomes after surgical resection of cardiac sarcoma in the multimodality treatment era. J Thorac Cardiovasc Surg; 2009 Jun;137(6):1454-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes after surgical resection of cardiac sarcoma in the multimodality treatment era.
  • Resection remains the primary therapy.
  • Especially in recent years, chemotherapy and radiation have been used adjunctively.
  • Concomitant valve surgery (repair or replacement) or coronary artery bypass grafting was performed in 9 and 3 patients, respectively.
  • Synchronous or staged resections of associated pulmonary metastases were performed in 6 and 2 patients, respectively.
  • Preoperative or postoperative chemotherapy was administered to 16 and 19 patients, respectively.
  • Patients who underwent surgical resection, radiofrequency ablation, or radiation treatment for tumor recurrence (local or metastatic, n = 7) had median survival of 47 months (range 16-119 months), whereas patients with no further intervention for recurrent disease (n = 7) had median survival of 25 months (range 8-34 months).
  • CONCLUSIONS: Multimodal therapy can achieve reasonable survival for patients with resected cardiac sarcomas.
  • Patients with local tumor recurrence or metastatic disease may still benefit from aggressive treatment.
  • [MeSH-minor] Adolescent. Adult. Aged. Cardiac Surgical Procedures. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Rate. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19464464.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Blackhall FH, O'brien M, Schmid P, Nicolson M, Taylor P, Milenkova T, Kennedy SJ, Thatcher N: A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer. J Thorac Oncol; 2010 Aug;5(8):1285-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer.
  • Three dose-limiting toxicities were reported in each treatment group: vandetanib + VC (pulmonary artery thrombosis and asymptomatic QTc prolongation [n = 2]); vandetanib + GC (peripheral ischemia [due to arterial occlusion], pulmonary embolism, and limb venous thrombosis).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Squamous Cell / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Piperidines / administration & dosage. Quinazolines / administration & dosage. Survival Rate. Tissue Distribution. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20661087.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 0 / Piperidines; 0 / Quinazolines; 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


5. Kwak HJ, Lee SJ, Lee YH, Ryu CH, Koh KN, Choi HY, Koh GY: Angiopoietin-1 inhibits irradiation- and mannitol-induced apoptosis in endothelial cells. Circulation; 2000 May 16;101(19):2317-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ang1 also prevented apoptosis in cultured endothelial cells from porcine pulmonary and coronary arteries and in endothelial cells of explanted rat aorta.
  • Pretreatment with Ang1 could be beneficial in maintaining normal endothelial cell integrity during intracoronary irradiation or systemic mannitol therapy.
  • [MeSH-major] Apoptosis / drug effects. Endothelium, Vascular / drug effects. Endothelium, Vascular / radiation effects. Mannitol / pharmacology. Membrane Glycoproteins / pharmacology. Proto-Oncogene Proteins
  • [MeSH-minor] Angiopoietin-1. Animals. Cells, Cultured. Coronary Vessels / cytology. Coronary Vessels / drug effects. Cytokines / pharmacology. Dose-Response Relationship, Drug. Growth Substances / pharmacology. Humans. Male. Muscle, Smooth, Vascular / cytology. Muscle, Smooth, Vascular / drug effects. Neoplasm Proteins / physiology. Phosphatidylinositol 3-Kinases / physiology. Pulmonary Artery / cytology. Pulmonary Artery / drug effects. Rats. Rats, Sprague-Dawley. Receptor, TIE-2. Swine. Umbilical Veins / cytology. Umbilical Veins / drug effects. Umbilical Veins / radiation effects

  • Hazardous Substances Data Bank. D-MANNITOL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10811601.001).
  • [ISSN] 1524-4539
  • [Journal-full-title] Circulation
  • [ISO-abbreviation] Circulation
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / ANGPT1 protein, human; 0 / Angiopoietin-1; 0 / Angpt1 protein, rat; 0 / Cytokines; 0 / Growth Substances; 0 / MEN1 protein, human; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins; 3OWL53L36A / Mannitol; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Receptor, TIE-2
  •  go-up   go-down


6. Veronesi G, Solli PG, Leo F, D'Aiuto M, Pelosi G, Leon ME, De Braud F, Spaggiari L, Pastorino U: Low morbidity of bronchoplastic procedures after chemotherapy for lung cancer. Lung Cancer; 2002 Apr;36(1):91-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low morbidity of bronchoplastic procedures after chemotherapy for lung cancer.
  • OBJECTIVE: To evaluate if induction chemotherapy, with or without irradiation, represents an additional risk factor for early and late morbidity and perioperative mortality in bronchoplastic procedures for lung cancers.
  • METHODS: From January 1998 to January 2001, 27 patients underwent a bronchial sleeve resection after induction treatment at the European Institute of Oncology in Milan.
  • They represent 7% of lung cancer resections (387) and 27% of those performed after neoadjuvant treatment (100 cases).
  • Twenty-four patients (89%) received a preoperative cisplatin based polichemotherapy, and three cases (11%) a chemo-radiation therapy.
  • A resection of tracheal carina was associated in three cases and a vascular resection in 10 (five vena cava and five pulmonary artery).
  • Perioperative morbidity of the study group (group 1) was compared with that of patients submitted to sleeve resection without neoadjuvant treatment (group 2), or standard pneumonectomy after induction treatment (group 3).
  • Only one late anastomotic stricture occurred after postoperative radiation treatment.
  • CONCLUSIONS: Preoperative chemotherapy or combination of chemo-radio therapy is not associated with an additional risk of anastomotic complications in bronco and angioplastic procedures.
  • Parenchyma sparing resection is a valid option for selected patients with locally advanced lung cancer after induction treatment.
  • A longer follow up is necessary to evaluate efficacy of the procedure in term of survival and local control.
  • [MeSH-major] Cisplatin / therapeutic use. Deoxycytidine / analogs & derivatives. Lung Neoplasms / drug therapy. Lung Neoplasms / surgery. Pneumonectomy / methods
  • [MeSH-minor] Adult. Aged. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / radiotherapy. Carcinoma, Small Cell / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Female. Humans. Lymph Node Excision. Male. Mediastinum / radiation effects. Middle Aged. Neoplasm Staging. Prospective Studies. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11891039.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Kramm T, Gaumann A, Heussel CP, Dahm M, Oelert H, Mayer E: [Surgical management of pulmonary artery sarcoma]. Dtsch Med Wochenschr; 2001 Dec 14;126(50):1423-7
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical management of pulmonary artery sarcoma].
  • [Transliterated title] Chirurgische Therapie des Pulmonalarteriensarkoms.
  • BACKGROUND AND OBJECTIVES: Pulmonary artery sarcoma is a rare neoplasm and possibly unnoticed cause of pulmonary hypertension.
  • The presentation is one of central pulmonary artery obstruction and progressive right-heart failure.
  • In most cases, the diagnosis of malignancy is confirmed post mortem.
  • We report the outcome of eight patients with primary pulmonary artery sarcomas.
  • NYHA functional class III/IV: n = 5/3) were referred for further evaluation of pulmonary hypertension.
  • Malignancy was suspected in six of these patients by means of computed tomography (CT) and magnetic resonance tomography (MRT).
  • In two patients diagnosis was established during pulmonary thromboendarterectomy based on histological examination of frozen sections.
  • Operative procedures consisted of gross tumor resection with prosthetic replacement (n = 3) or reconstruction (n = 5) of central parts of the pulmonary vessels.
  • Seven patients received adjuvant radio- and/or chemotherapy.
  • Two patients are alive 3 and 39 months after primary surgery with evidence of pulmonary metastases.
  • CONCLUSIONS: In patients with primary pulmonary artery sarcoma, emphasis must be placed on early identification which can be achieved by CT and MRT.
  • Adjuvant therapy might bring additional benefit.
  • [MeSH-major] Hypertension, Pulmonary / etiology. Pulmonary Artery / surgery. Sarcoma / surgery. Vascular Neoplasms / surgery
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Leiomyosarcoma / complications. Leiomyosarcoma / diagnosis. Leiomyosarcoma / surgery. Magnetic Resonance Imaging. Male. Mesenchymoma / complications. Mesenchymoma / diagnosis. Mesenchymoma / surgery. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local / pathology. Pneumonectomy. Prognosis. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pulmonary Hypertension.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11743678.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


8. He W, Jiang G, Xie B, Liu M: Radical resection of a pulmonary blastoma involving the pulmonary artery. Eur J Cardiothorac Surg; 2008 Sep;34(3):695-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical resection of a pulmonary blastoma involving the pulmonary artery.
  • Pulmonary blastoma is a rare malignant lesion with a poor prognosis.
  • We described a case of a 47-year-old woman with a large biphasic pulmonary blastoma, involving the left pulmonary artery.
  • Under cardiopulmonary bypass, it was treated with radical left intrapericardial pneumonectomy and pulmonary thromboendarterectomy.
  • Subsequent chemotherapy and radiotherapy was used.
  • [MeSH-major] Lung Neoplasms / surgery. Pulmonary Artery / surgery. Pulmonary Blastoma / surgery
  • [MeSH-minor] Endarterectomy / methods. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Invasiveness. Pneumonectomy / methods. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Blastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18579394.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


9. Katz ES, Shah A, Rosenzweig BP, Tunick PA, Kronzon I: Bilateral pulmonary artery compression and obstruction by tumor: diagnosis by unusual Doppler flow patterns. J Am Soc Echocardiogr; 2003 Feb;16(2):185-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral pulmonary artery compression and obstruction by tumor: diagnosis by unusual Doppler flow patterns.
  • Pulmonary artery obstruction may be caused by tumor within or external to the arteries.
  • Presented here is a patient with life-threatening compromise in pulmonary flow that was caused by a pulmonary neoplasm.
  • The Doppler echocardiogram showed subtotal narrowing of the right pulmonary artery and total occlusion of the left pulmonary artery.
  • In addition, the beneficial effects of chemotherapy were documented by Doppler.
  • [MeSH-major] Lung Neoplasms / complications. Lung Neoplasms / ultrasonography. Pulmonary Artery. Ultrasonography, Doppler, Color
  • [MeSH-minor] Constriction, Pathologic. Female. Humans. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12574747.001).
  • [ISSN] 0894-7317
  • [Journal-full-title] Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
  • [ISO-abbreviation] J Am Soc Echocardiogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Millet A, Morel H, Sanchez O, Meyer G, Le Roy Ladurie F, Dartevelle P, Dulmet E, Goarant E, Curran Y: [Invasion of the pulmonary artery by an undifferentiated carcinoma]. Rev Mal Respir; 2008 Jan;25(1):63-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Invasion of the pulmonary artery by an undifferentiated carcinoma].
  • [Transliterated title] Obstruction tumorale de l'artère pulmonaire par un carcinome indifférencié
  • INTRODUCTION: The diagnosis of chronic obstruction of the pulmonary artery is difficult.
  • We present the case of a woman with an invasive, undifferentiated carcinoma of the pulmonary artery.
  • This was evaluated by computed tomography which showed a defect in the main pulmonary artery.
  • There was no clinical or radiological improvement following anticoagulant treatment for two months.
  • A repeat CT scan showed a persisting intravascular defect and the diagnoses considered included post-embolic pulmonary arterial hypertension and angiosarcoma.
  • CONCLUSION: Invasion of the pulmonary artery by angiosarcoma or other tumour is part of the differential diagnosis of chronic thromboembolic disease.
  • The diagnosis rests on histology obtained by an intravascular or surgical procedure.
  • The patient died despite two courses of chemotherapy and targeted therapy with erlotinib.
  • [MeSH-major] Carcinoma / pathology. Lung Neoplasms / pathology. Pulmonary Artery / pathology. Vascular Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18288053.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


11. Miura S, Meirmanov S, Nakashima M, Hayashi T, Abe K, Tamaru N, Miyahara Y, Sekine I: Intimal sarcoma of the pulmonary artery: report of an autopsy case. Pathol Res Pract; 2005;201(6):469-74
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intimal sarcoma of the pulmonary artery: report of an autopsy case.
  • Primary pulmonary artery sarcomas (PASs) are rare and lethal tumors.
  • They are easily misdiagnosed as chronic pulmonary embolism, mediastinal mass or tumor emboli, which delay a proper treatment.
  • Although the advanced technologies are now increasingly being used, their diagnosis is usually hard to establish preoperatively at the present time.
  • Although a PAS had been suspected, the final diagnosis of pulmonary intimal sarcoma was made only postoperatively by histological and immunohistochemical examination.
  • The patient died 8 months after the operation because of tumor growth progression, despite adjuvant chemotherapy and radiation therapy.
  • Although pulmonary intimal sarcomas are usually of poorly differentiated mesenchymal malignancy, most reported cases are immunohistochemically positive for vimentin, alpha-smooth muscle actin (SMA), and/or desmin, therefore resembling leiomyosarcomas.
  • However, the diagnosis of leiomyosarcoma should not be made on the basis of immunostains in the absence of typical morphologic features, and PAS, like the present case, should be more appropriately classified as intimal sarcoma according to the new WHO Classification of Tumours of Soft Tissue and Bone published in 2002.
  • [MeSH-major] Lung Neoplasms / secondary. Pulmonary Artery / pathology. Sarcoma / secondary. Tunica Intima / pathology. Vascular Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Endarterectomy. Fatal Outcome. Female. Humans. Neoplasm Recurrence, Local. Radiography, Thoracic. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16136754.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


12. Kamigaki M, Yamazaki K, Tsujino I, Suga M, Sakaue S, Dosaka-Akita H, Nishimura M: Small cell carcinoma of the lung exclusively localized within the left descending pulmonary artery. Chest; 2005 Jun;127(6):2273-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma of the lung exclusively localized within the left descending pulmonary artery.
  • We encountered a 69-year-old woman displaying a filling defect within the left descending pulmonary artery (PA) on a chest CT scan and pulmonary angiography.
  • A subsequent 2-[18F]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) scan demonstrated focal uptake in the left hilum.
  • The patient underwent concurrent radiation therapy and chemotherapy with cisplatin and etoposide, resulting in tumor shrinkage and recanalization of the involved PA.
  • This is the first case of small cell carcinoma localized exclusively within the PA, and positive findings on FDG-PET facilitated the unexpected diagnosis.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / therapy. Lung Neoplasms / pathology. Lung Neoplasms / therapy. Pulmonary Artery / pathology
  • [MeSH-minor] Aged. Angiography / methods. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Combined Modality Therapy. Dose Fractionation. Female. Follow-Up Studies. Humans. Immunohistochemistry. Neoplasm Staging. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Chest. 2005 Jun;127(6):1889 [15947298.001]
  • (PMID = 15947349.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Kogure T, Iwasaki T, Ueno Y, Kanno N, Fukushima K, Yamagiwa Y, Nagasaki F, Kakazu E, Matsuda Y, Kido O, Nakagome Y, Ninomiya M, Shimosegawa T: Complete remission of a case of hepatocellular carcinoma with tumor invasion in inferior vena cava and with pulmonary metastasis successfully treated with repeated arterial infusion chemotherapy. Hepatogastroenterology; 2007 Oct-Nov;54(79):2113-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission of a case of hepatocellular carcinoma with tumor invasion in inferior vena cava and with pulmonary metastasis successfully treated with repeated arterial infusion chemotherapy.
  • We report the case of a patient having hepatocellular carcinoma with tumor invasion to the inferior vena cava and with multiple pulmonary metastases who was treated with repeated one-shot administration of epirubicin, cisplatin, and mitomycin C by hepatic artery and bronchial artery, which led to complete remission.
  • A 72-year-old woman was diagnosed with infiltrative hepatocellular carcinoma with Vv3, multiple intrahepatic metastases, and multiple pulmonary metastases associated with compensated liver cirrhosis.
  • One-shot infusion of epirubicin, cisplatin, and mitomycin C was performed through proper hepatic artery and bronchial artery for twice at eight weeks of intervals.
  • Pulmonary metastases disappeared and intrahepatic lesions indicated marked shrinkage leaving a scar-like lesion with decreases in tumor markers.
  • After six months and 20 months, tumor markers indicated increasing tendency but no evident recurrence was found by computed tomography or hepatic arteriography.
  • One-shot infusion of the same regimens through proper hepatic artery was performed and tumor markers decreased to normal levels.
  • After 14 months of the last therapy, no evidence of recurrence has been found on image analysis or in tumor markers.
  • This arterial infusion therapy is well tolerated for the patients with compensated liver cirrhosis and might be promising for the effective treatment of advanced hepatocellular carcinoma with pulmonary metastases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / pathology. Infusions, Intra-Arterial. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology. Lung Neoplasms / secondary. Vena Cava, Inferior / pathology
  • [MeSH-minor] Aged. Bronchial Arteries. Female. Hepatic Artery. Humans. Neoplasm Invasiveness. Remission Induction. Retreatment. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18251171.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


14. Nakanishi M, Demura Y, Umeda Y, Mizuno S, Ameshima S, Chiba Y, Ishizaki T: Multi-arterial infusion chemotherapy for non-small cell lung carcinoma--significance of detecting feeding arteries and tumor staining. Lung Cancer; 2008 Aug;61(2):227-34
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multi-arterial infusion chemotherapy for non-small cell lung carcinoma--significance of detecting feeding arteries and tumor staining.
  • The present study examines the significance of defining feeding arteries to arterial infusion chemotherapy for patients with non-small cell lung carcinoma.
  • We retrospectively studied feeding arteries and findings from 32 patients treated by arterial infusion chemotherapy.
  • We graded tumor staining by angiography and compared grade in the bronchial artery with that of total staining in all detected feeding arteries, and investigated the relationship between grade and treatment response.
  • Many feeding arteries were detected and the grade of total tumor staining in these patients was significantly higher than that of tumor staining in the bronchial artery.
  • Precise definition of feeding arteries and sufficient tumor staining are vital to ensure a successful outcome of arterial infusion chemotherapy for patients with NSCLC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bronchial Arteries / radiography. Carcinoma, Non-Small-Cell Lung / blood supply. Infusions, Intra-Arterial. Lung Neoplasms / blood supply
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Neovascularization, Pathologic. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18243405.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


15. Aketa A, Yamada G, Aketa K, Ohnishi T, Takahashi Y, Kudoh K, Tanaka S, Shiratori M, Takahashi H, Watanabe A, Satoh M, Abe S: [Two younger male patients with rapidly progressing pulmonary pleomorphic carcinoma]. Nihon Kokyuki Gakkai Zasshi; 2004 Feb;42(2):164-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two younger male patients with rapidly progressing pulmonary pleomorphic carcinoma].
  • We report 2 cases of pulmonary pleomorphic carcinoma.
  • However, we performed partial resection of the tumor because it had invaded the aorta, pulmonary artery, pericardium and pleura.
  • The pathological diagnosis was pleomorphic carcinoma, p-T4 N2 M0.
  • After the operation, we performed systemic chemotherapy, including cisplatin and irinotecanm with little effect (PD).
  • Pathological diagnosis was pleomorphic carcinoma, p-T4 N0 M0.
  • After the operation, the mediastinum was subjected to radiation therapy.
  • We performed systemic chemotherapy with substances including cisplatin, gemcitabine and vinorelbine, but with little effect (PD).
  • Both cases had rapidly growing neoplasms showing little sensitivity to chemotherapy or radiotherapy.
  • Pulmonary pleomorphic carcinoma is suggested to be type of lung cancer with a poor prognosis when the tumor is not resected in the early stages.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / therapy. Carcinoma, Giant Cell / diagnosis. Carcinoma, Giant Cell / therapy. Lung Neoplasms / diagnosis. Lung Neoplasms / therapy. Neoplasms, Multiple Primary
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Adult. Age Factors. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant. Disease Progression. Fatal Outcome. Humans. Lymph Node Excision. Male. Neoplasm Invasiveness. Neoplasm Staging. Pneumonectomy. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15007917.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


16. Demmy TL, Wagner-Mann C, Allen A: Isolated lung chemotherapeutic infusions for treatment of pulmonary metastases: a pilot study. J Biomed Sci; 2002 Jul-Aug;9(4):334-8
Hazardous Substances Data Bank. P-AMINOHIPPURIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated lung chemotherapeutic infusions for treatment of pulmonary metastases: a pilot study.
  • A pilot study was designed to determine the feasibility of combining minimally invasive surgery techniques and cardiac surgical catheter technology to deliver high-dose unilateral pulmonary chemotherapy.
  • Single lung ventilation general anesthesia was combined with catheter-based left pulmonary artery (PA) control in 4 mongrel dogs. p-Aminohippuric acid (PAH) was used to quantify leakage of pulmonary arterial infusate.
  • Dissection of cranial and caudal pulmonary veins followed methods used in minimally invasive pulmonary lobectomy.
  • All animals survived the experimental procedure.
  • A volume (50 cm(3)) of infusate much smaller than the calculated pulmonary vascular volume caused less vascular overdistention and diffused throughout the pulmonary vascular bed within 3-5 min as verified by fluoroscopy.
  • 75% of the tracer remained in the lung at the completion of the 30-min dwell time.
  • The pulmonary circulation can be isolated by minimally invasive operative and catheter technology so that the pulmonary parenchyma can be exposed to a high concentration of a compound for at least 30 min in the canine model.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Chemotherapy, Cancer, Regional Perfusion / methods. Lung Neoplasms / drug therapy
  • [MeSH-minor] Animals. Catheterization. Dogs. Humans. Lung / surgery. Neoplasm Metastasis. Pilot Projects. Pulmonary Artery / surgery. Thoracic Surgery, Video-Assisted / methods. p-Aminohippuric Acid / urine

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 National Science Council, ROC and S. Karger AG, Basel
  • (PMID = 12145531.001).
  • [ISSN] 1021-7770
  • [Journal-full-title] Journal of biomedical science
  • [ISO-abbreviation] J. Biomed. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Y79XT83BJ9 / p-Aminohippuric Acid
  •  go-up   go-down


17. Gaumann A, Tews DS, Mentzel T, Petrow PK, Mayer E, Otto M, Kirkpatrick CJ, Kriegsmann J: Expression of drug resistance related proteins in sarcomas of the pulmonary artery and poorly differentiated leiomyosarcomas of other origin. Virchows Arch; 2003 Jun;442(6):529-37
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of drug resistance related proteins in sarcomas of the pulmonary artery and poorly differentiated leiomyosarcomas of other origin.
  • Mechanisms involved in drug resistance include reduced cellular drug accumulation, drug detoxification as well as alterations in drug target specificity.
  • In seven sarcomas of the pulmonary artery (SPA) and ten leiomyosarcomas of other origin, we studied the immunohistochemical expression of P-glycoprotein (P-gp), multidrug-resistance protein (MRP), lung resistance protein (LRP), metallothionein (MT) and topoisomerase IIalpha.
  • Topoisomerase IIalpha was expressed at high levels in tissue of primary tumours as well as recurrent tumours.
  • P-gp, but not MRP, may play a role in the development of drug resistance.
  • P-gp, LRP and topoisomerase IIalpha contribute to drug resistance through expression in tumour-associated vessels.
  • Our findings underline the fact that multiple factors contribute to chemoresistance and that examination of a spectrum of relevant molecules is probably necessary to plan the best therapy.
  • [MeSH-major] Drug Resistance, Neoplasm. Leiomyosarcoma / metabolism. Neoplasm Proteins / metabolism. Neoplasms, Vascular Tissue / metabolism. Pulmonary Artery / pathology
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins. Female. Humans. Male. Metallothionein / metabolism. Middle Aged. P-Glycoprotein / metabolism. P-Glycoproteins / metabolism. Survival Rate. Vault Ribonucleoprotein Particles / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1989 Nov 15;81(22):1732-5 [2553992.001]
  • [Cites] Virchows Arch. 1994;424(3):273-7 [8186891.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Jan;121(1):77-82 [11135162.001]
  • [Cites] Br J Cancer. 1997;76(4):445-50 [9275020.001]
  • [Cites] Am J Pathol. 1996 Sep;149(3):853-8 [8780389.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):386-91 [7812971.001]
  • [Cites] Int J Cancer. 1996 Jan 17;65(2):230-7 [8567122.001]
  • [Cites] Exp Cell Res. 1990 Oct;190(2):212-7 [2209724.001]
  • [Cites] Gen Pharmacol. 1996 Jun;27(4):565-73 [8853285.001]
  • [Cites] Am J Pathol. 1996 Mar;148(3):877-87 [8774142.001]
  • [Cites] Anticancer Drugs. 1992 Aug;3(4):323-30 [1330080.001]
  • [Cites] Cancer Res. 1983 Jun;43(6):2918-26 [6850603.001]
  • [Cites] J Cell Biol. 1990 Apr;110(4):895-901 [1691193.001]
  • [Cites] Acta Pathol Jpn. 1988 Jul;38(7):883-96 [3055809.001]
  • [Cites] Nat Med. 1995 Jun;1(6):578-82 [7585126.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5902-10 [7954421.001]
  • [Cites] Gen Pharmacol. 1994 Nov;25(7):1297-310 [7896039.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):21-6 [11438449.001]
  • [Cites] Cancer Res. 1993 Dec 1;53(23):5663-8 [8242621.001]
  • [Cites] Mod Pathol. 2001 Sep;14(9):886-91 [11557785.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Sep;9(3):242-9 [11556752.001]
  • [Cites] J Neurooncol. 2000 Dec;50(3):227-37 [11263502.001]
  • [Cites] Cancer Res. 1993 Apr 1;53(7):1475-9 [7680954.001]
  • [Cites] J Histochem Cytochem. 1990 Sep;38(9):1277-87 [1974900.001]
  • [Cites] Anticancer Res. 1996 Jul-Aug;16(4A):1867-80 [8712715.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):836-42 [11550155.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8822-6 [7916458.001]
  • [Cites] Virchows Arch. 2001 Nov;439(5):668-74 [11764388.001]
  • [Cites] Acta Neuropathol. 1991;82(6):516-9 [1723831.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Nov;84(21):7668-71 [2823270.001]
  • [Cites] Annu Rev Biochem. 1989;58:137-71 [2570548.001]
  • [Cites] Leukemia. 1996 Jul;10 Suppl 3:S10-S17 [8656694.001]
  • [Cites] Cancer. 1997 Jun 15;79(12):2336-44 [9191521.001]
  • [Cites] Br J Cancer. 1998 Feb;77(4):556-61 [9484811.001]
  • [Cites] Br J Urol. 1997 Jul;80(1):11-7 [9240173.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6969-75 [1360873.001]
  • [Cites] Cell. 1994 May 20;77(4):491-502 [7910522.001]
  • [Cites] Mod Pathol. 2000 May;13(5):542-7 [10824926.001]
  • (PMID = 12743815.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0 / Neoplasm Proteins; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; 9038-94-2 / Metallothionein; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


18. Lumia D, Laganà D, Verna E, Mangini M, Canì A, Carrafiello G, Fugazzola C: Recurrence of intracardiac large B-cell non-Hodgkin's lymphoma (NHL) encasing and nearly obliterating the right coronary artery: a case report. Minerva Chir; 2010 Jun;65(3):383-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of intracardiac large B-cell non-Hodgkin's lymphoma (NHL) encasing and nearly obliterating the right coronary artery: a case report.
  • A 73-year-old man affected by non-Hodgkin lymphoma (NHL) treated with four cycle of chemotherapy and radiotherapy was admitted to the Emergency Department for chest pain.
  • Echocardiography showed a mass inside the right ventricle obstructing blood outflow in the pulmonary artery.
  • The ECG-gated angio-multidetector computed tomography (MDCT) examination confirmed a solid mass in the right ventricle encasing the proximal-middle tract of the right coronary artery (RCA); RCA stenosis was confirmed by coronary angiography.
  • After trans-thoracic CT-guided biopsy the mass was characterized as a recurrence of NHL and the patient started a new cycle of chemotherapy.
  • [MeSH-major] Coronary Stenosis / etiology. Heart Neoplasms / complications. Lymphoma, Large B-Cell, Diffuse / complications. Neoplasm Recurrence, Local / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20668424.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


19. Sherer DM, Stimphil RG, Santoso P, Demetus S, Abulafia O: Stage IV large B cell lymphoma presenting as gigantomastia and pulmonary hypertension. Obstet Gynecol; 2004 May;103(5 Pt 2):1061-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage IV large B cell lymphoma presenting as gigantomastia and pulmonary hypertension.
  • BACKGROUND: Gigantomastia is a rare complication of pregnancy usually associated with benign conditions, including end-organ hypersensitivity to normal hormone levels, penicillamine therapy, mirror syndrome, and benign or glandular fibroadenomas.
  • Echocardiography performed because of the patient's tachypnea and tachycardia disclosed pulmonary hypertension.
  • After spontaneous delivery, core needle breast and axillary lymph node biopsies and computerized tomography imaging were performed, and stage IV diffuse large B cell lymphoma with infiltration of the breasts was confirmed.
  • The patient responded to systemic chemotherapy with resolution of the gigantomastia and pulmonary artery hypertension.
  • CONCLUSION: This case demonstrates that systemic malignancies such as diffuse large B cell lymphoma should be considered in the differential diagnosis of gigantomastia during pregnancy.
  • In addition, malignancy-related pulmonary hypertension during pregnancy may be reversible after chemotherapy, as reported in nonpregnant patients.
  • [MeSH-major] Breast Diseases / etiology. Hypertension, Pulmonary / etiology. Lymphoma, B-Cell / complications. Lymphoma, Large B-Cell, Diffuse / complications. Pregnancy Complications, Neoplastic / pathology
  • [MeSH-minor] Adult. Axilla. Biopsy, Needle. Breast / pathology. Female. Humans. Lymph Nodes / pathology. Neoplasm Staging. Pregnancy


20. Morbini P, Riboni R, Tomaselli S, Rossi A, Magrini U: Eber- and LMP-1-expressing pulmonary lymphoepithelioma-like carcinoma in a Caucasian patient. Hum Pathol; 2003 Jun;34(6):623-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eber- and LMP-1-expressing pulmonary lymphoepithelioma-like carcinoma in a Caucasian patient.
  • Despite advanced locoregional disease, with neoplastic infiltration of the main right bronchus, the carina, and the pulmonary artery, which prevented surgical resection, partial response and 1-year symptom-free follow-up were achieved after combined chemotherapy and radiotherapy.
  • [MeSH-minor] Adult. Antigens, Viral / analysis. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor. Cell Nucleus / metabolism. Cell Nucleus / pathology. Cell Nucleus / virology. Combined Modality Therapy. Humans. Immunohistochemistry. Male. Neoplasm Staging. Palliative Care. Radiotherapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12827618.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / RNA-Binding Proteins; 0 / Ribosomal Proteins; 0 / Viral Matrix Proteins; 135844-68-7 / RPL22 protein, human
  •  go-up   go-down


21. Buchbinder D, Steinberg G, Linetsky M, Casillas J: Moyamoya in a child treated with interferon for recurrent osteosarcoma. J Pediatr Hematol Oncol; 2010 Aug;32(6):476-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SUMMARY: Moyamoya is a cerebral vasculopathy of unknown etiology rarely described as a late effect after the treatment of childhood cancer.
  • We describe a 12-year-old female who developed moyamoya after the completion of systemic chemotherapy, surgery, and adjuvant interferon alpha for osteosarcoma with pulmonary metastases.
  • Given the importance of characterizing late effects after the treatment of childhood cancer, the potential role of interferon alpha in the development of moyamoya is discussed.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Bone Neoplasms / drug therapy. Interferon-alpha / adverse effects. Moyamoya Disease / chemically induced. Neoplasm Recurrence, Local / drug therapy. Osteosarcoma / drug therapy
  • [MeSH-minor] Carotid Artery Diseases / chemically induced. Carotid Artery Diseases / pathology. Cerebral Arterial Diseases / chemically induced. Cerebral Arterial Diseases / pathology. Cerebral Infarction / chemically induced. Cerebral Infarction / pathology. Chemotherapy, Adjuvant / adverse effects. Child. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Magnetic Resonance Angiography. Methotrexate / administration & dosage. Neoadjuvant Therapy. Thyroiditis, Autoimmune / chemically induced

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20562650.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


22. Hollaus PH, Wilfing G, Wurnig PN, Pridun NS: Risk factors for the development of postoperative complications after bronchial sleeve resection for malignancy: a univariate and multivariate analysis. Ann Thorac Surg; 2003 Mar;75(3):966-72
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prospectively documented data were age, gender, side, type of bronchial reconstruction, extended resection, histology, TNM stage, diseased lobe, and bronchial tumour occlusion.
  • Cardiovascular (CV) risk factors included heart disease, arterial hypertension, cerebro-occlusive disease, peripheral artery disease of the lower extremities, diabetes mellitus, and abdominal aortic aneurysm.
  • Non-CV risk factors included neoadjuvant chemotherapy, alcoholism, lung disease, sleep apnea, history of recent pneumococcal sepsis, and repeat thoracotomy.
  • Groups were assembled according to the presence or absence of any non-CV risk factor, neoadjuvant chemotherapy, and alcoholism.
  • Coronary artery disease (p = 0.02, OR = 0.062) and the combination of two respiratory risk factors (p = 0.008, OR = 0.062) were predictive for septic complications.
  • Peripheral artery disease (p = 0.024, OR = 0.28), moderate (p = 0.01, OR = 0.13) and severe chronic obstructive pulmonary disease (p = 0.018, OR = 0.11), and extended resections (p = 0.003, OR = 0.017.) were predictive for aseptic complications.
  • [MeSH-major] Bronchi / surgery. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Small Cell / surgery. Cardiovascular Diseases / complications. Lung Neoplasms / surgery. Pneumonectomy / methods. Postoperative Complications / etiology. Pulmonary Disease, Chronic Obstructive / complications
  • [MeSH-minor] Adult. Aged. Anastomosis, Surgical / methods. Cause of Death. Female. Health Status Indicators. Humans. Male. Mathematical Computing. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - COPD.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12645725.001).
  • [ISSN] 0003-4975
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


23. Rea F, Marulli G, Schiavon M, Zuin A, Hamad AM, Rizzardi G, Perissinotto E, Sartori F: A quarter of a century experience with sleeve lobectomy for non-small cell lung cancer. Eur J Cardiothorac Surg; 2008 Sep;34(3):488-92; discussion 492
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Sleeve lobectomy represents an effective and widely accepted surgical therapy for non-small cell lung carcinoma (NSCLC).
  • In 39 (19.6%) patients a vascular procedure was associated.
  • Nineteen (9.5%) patients had preoperative radiotherapy, 14 (7%) preoperative chemotherapy and 10 (5%) chemoradiotherapy.
  • CONCLUSIONS: Sleeve lobectomy is a safe and effective therapy for selected patients with NSCLC.
  • Vascular procedures and the use of induction chemotherapy did not increase mortality and morbidity; otherwise, the use of preoperative radiotherapy is not recommended.
  • This emphasises the importance of a learning curve and encourages the performance of this procedure in experienced centres.
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Epidemiologic Methods. Female. Humans. Male. Middle Aged. Neoplasm Staging. Pulmonary Artery / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18579399.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


24. Mackay HJ, O'Brien M, Hill S, Lees SM, Thatcher N, Smith IE, Dunlop DJ: A phase II study of carboplatin and vinorelbine in patients with poor prognosis small cell lung cancer. Clin Oncol (R Coll Radiol); 2003 Jun;15(4):181-5
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with good prognosis disease were included who were not medically fit to tolerate conventional chemotherapy.
  • Activity was assessed primarily as response rate and secondarily in terms of toxicity, time to progression and survival.
  • PATIENTS AND METHODS: Fifty-eight patients, 37 men and 21 women, with histologically or cytologically confirmed SCLC, who had bi-dimensionally measurable disease, with ECOG performance status > or = 2, with adequate haematological, hepatic and renal function received first-line chemotherapy with carboplatin (AUC x 5) day 1 and vinorelbine (30 mg/m2) days 1 and 8 of a 28-day cycle.
  • Response was assessed after every two cycles of chemotherapy, with patients receiving a maximum of six cycles of treatment.
  • RESULTS: The combination of carboplatin and vinorelbine is an active regimen in the treatment of SCLC, with an overall intention-to-treat response rate of 55% [95% confidence interval (CI): 42-68%] with six (10%) of patients having a complete response.
  • Median time to progression was 18 weeks (95% CI: 15-21 weeks).
  • Ten patients failed to complete two cycles of treatment, and were not evaluable for response for the following reasons: septic death (1 neutropaenic, 1 no myelotoxicity), non-toxic death (1 tumour eroded through the pulmonary artery, 1 ischaemic heart disease) ischaemic heart disease (1) and patient decision (5).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Carcinoma, Small Cell / drug therapy. Lung Neoplasms / drug therapy. Vinblastine / analogs & derivatives
  • [MeSH-minor] Carboplatin / administration & dosage. Carboplatin / adverse effects. Female. Humans. Male. Neoplasm Staging. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12846495.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; BG3F62OND5 / Carboplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


25. Reardon MJ, Walkes JC, Benjamin R: Therapy insight: malignant primary cardiac tumors. Nat Clin Pract Cardiovasc Med; 2006 Oct;3(10):548-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy insight: malignant primary cardiac tumors.
  • Malignant cardiac tumors, however, continue to pose a therapeutic challenge to cardiac surgeons and oncologists because of the technical difficulty involved in extensive cardiac resections and the aggressive biological nature of the tumors.
  • The majority of malignant cardiac tumors are sarcomas and can be categorized as right heart sarcoma, left heart sarcoma or pulmonary artery sarcoma.
  • A combination of chemotherapy and surgical resection is the preferred therapy.
  • Left heart sarcomas, although large, are often less infiltrative and metastasize later than right heart sarcomas, but a similar approach to treatment is usually employed.
  • We have developed and employed the technique of cardiac autotransplantation, which involves cardiac excision, ex vivo tumor resection with cardiac reconstruction, and cardiac reimplantation, to lessen these technical difficulties.
  • Pulmonary artery sarcomas can be treated by radiotherapy, as well as by the other therapies, because the myocardium can be avoided by the radiation fields.
  • Surgical resection of this sarcoma type often requires pneumonectomy and can require pulmonary root replacement.
  • [MeSH-major] Heart Neoplasms / surgery. Hemangiosarcoma / surgery. Histiocytoma, Malignant Fibrous / surgery. Pulmonary Artery / surgery. Vascular Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cardiac Surgical Procedures. Chemotherapy, Adjuvant. Humans. Neoplasm Invasiveness. Neoplasm Metastasis. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16990840.001).
  • [ISSN] 1743-4297
  • [Journal-full-title] Nature clinical practice. Cardiovascular medicine
  • [ISO-abbreviation] Nat Clin Pract Cardiovasc Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 23
  •  go-up   go-down


26. Park BJ, Bacchetta M, Bains MS, Downey RJ, Flores R, Rusch VW, Girardi LN: Surgical management of thoracic malignancies invading the heart or great vessels. Ann Thorac Surg; 2004 Sep;78(3):1024-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We reviewed our experience of 10 patients treated surgically, either primarily or as a component of multimodality therapy, to assess feasibility and results.
  • RESULTS: Histologic diagnoses included soft tissue sarcoma (n = 7), squamous cell carcinoma (n = 1), malignant thymoma (n = 1), and mediastinal teratoma (n = 1).
  • Three patients underwent induction chemotherapy.
  • Structures resected included superior vena cava (n = 5), left atrium (n = 4), right atrium (n = 2), descending aorta (n = 1), and main pulmonary artery (n = 1).
  • Concomitant anatomic pulmonary resections were performed in 3 patients.
  • Six patients underwent postoperative systemic therapy.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Heart Neoplasms / surgery. Neoplasm Invasiveness / pathology. Sarcoma / surgery. Teratoma / surgery. Thymoma / surgery. Vascular Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Aorta, Thoracic / pathology. Cardiopulmonary Bypass. Chemotherapy, Adjuvant. Echocardiography, Transesophageal. Female. Follow-Up Studies. Heart Atria / pathology. Humans. Length of Stay. Male. Middle Aged. Pulmonary Artery / pathology. Retrospective Studies. Survival Rate. Thymus Neoplasms / diagnosis. Thymus Neoplasms / pathology. Tomography, X-Ray Computed. Treatment Outcome. Vena Cava, Superior / pathology

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15337042.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


27. Blackmon SH, Patel A, Reardon MJ: Management of primary cardiac sarcomas. Expert Rev Cardiovasc Ther; 2008 Oct;6(9):1217-22
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The biological behavior of cardiac sarcomas is similar to all soft-tissue sarcomas.
  • Although histologic type affects behavior, survival is dependent on the histologic grade.
  • Chemotherapy and radiation therapy are not adequate for long-term survival.
  • Based on the surgical approach and clinical behavior, cardiac sarcomas can be classified as right heart sarcomas, left heart sarcomas and pulmonary artery sarcomas.
  • Our limited - albeit the most extensive - experience with cardiac sarcomas has helped improve survival compared with chemotherapy alone.
  • They are usually treated with chemotherapy prior to extensive resection.
  • Pulmonary artery sarcomas tend to be confined to the pulmonary artery, often causing severe right heart failure and metastasize later than right heart sarcomas.
  • Adjuvant therapy is recommended for all patients given that excellent local control is often achieved with surgery, yet long-term survival is often poor due to metastatic recurrence.
  • Pulmonary artery sarcomas allow for radiation therapy in addition to chemotherapy for neoadjuvant control, as the myocardium can be avoided.
  • [MeSH-major] Cardiac Surgical Procedures / methods. Heart Neoplasms / therapy. Sarcoma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Heart Transplantation / methods. Humans. Neoplasm Metastasis. Survival Rate. Transplantation, Autologous

  • MedlinePlus Health Information. consumer health - Heart Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18939909.001).
  • [ISSN] 1744-8344
  • [Journal-full-title] Expert review of cardiovascular therapy
  • [ISO-abbreviation] Expert Rev Cardiovasc Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 35
  •  go-up   go-down


28. Van Schil P, Den Hengst W, Hendriks J: Surgical resection of lung metastases including the role of locoregional therapy. Verh K Acad Geneeskd Belg; 2010;72(1-2):99-114
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resection of lung metastases including the role of locoregional therapy.
  • Although no randomized trials are available, surgical resection is a widely accepted treatment for selected patients with pulmonary metastases.
  • For this reason, locoregional therapies are extensively investigated at the present time.
  • Due to toxicity of high doses of intravenous chemotherapy, the main purpose is to deliver high-dose chemotherapy to the lung without systemic side-effects.
  • Chemo-embolization, pulmonary artery infusion and isolated lung perfusion are most intensively studied.
  • These techniques were found to be feasible and are able to deliver a high local concentration of chemotherapeutic drugs.
  • [MeSH-minor] Humans. Neoplasm Metastasis. Neoplasm Recurrence, Local. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20726442.001).
  • [ISSN] 0302-6469
  • [Journal-full-title] Verhandelingen - Koninklijke Academie voor Geneeskunde van België
  • [ISO-abbreviation] Verh. K. Acad. Geneeskd. Belg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


29. Sanfilippo NJ, Hsi A, DeNittis AS, Ginsberg GG, Kochman ML, Friedberg JS, Hahn SM: Toxicity of photodynamic therapy after combined external beam radiotherapy and intraluminal brachytherapy for carcinoma of the upper aerodigestive tract. Lasers Surg Med; 2001;28(3):278-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxicity of photodynamic therapy after combined external beam radiotherapy and intraluminal brachytherapy for carcinoma of the upper aerodigestive tract.
  • BACKGROUND AND OBJECTIVE: To describe the toxicity of photodynamic therapy (PDT) in patients with carcinoma of the upper aerodigestive tract who received prior treatment with external beam irradiation and intraluminal brachytherapy (IB).
  • Three patients who received prior treatment with external beam irradiation and IB were identified.
  • Two patients had esophageal carcinoma treated with combined chemotherapy and external beam irradiation (55.8 and 50.4 Gy) followed by IB (12 Gy and 35 Gy at 1 cm).
  • These patients then received PDT for treatment of recurrence (2 mg/kg Photofrin injection and 2 light applications: 630 nm, 150--200 J/cm, 200--400 mW/cm).
  • One patient had non-small cell lung cancer treated with external beam irradiation (60 Gy) followed by IB (36.1 Gy at 1 cm) and then received PDT for recurrence (1 mg/kg Photofrin injection and one light application: 630 nm, 150 J/cm, 200 mW/cm).
  • The other esophageal cancer patient developed quadriplegia due to an epidural abscess arising from a fistula with the diseased portion of the esophagus.
  • The lung cancer patient had massive hemoptysis after the procedure and died 2 days later.
  • Autopsy showed necrotizing arteritis of the right pulmonary artery.
  • CONCLUSION: Patients with upper aerodigestive tract carcinoma who have received treatment with both external beam irradiation and IB seem to be at higher risk for complications when treated with PDT.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / therapy. Lung Neoplasms / therapy. Neoplasm Recurrence, Local / drug therapy. Photochemotherapy / adverse effects
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brachytherapy. Combined Modality Therapy. Fatal Outcome. Female. Humans. Male. Middle Aged. Prognosis. Radiation Dosage. Risk Assessment

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11295765.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Sonobe M, Bando T, Date H: Peripheral primitive neuroectodermal tumour of the chest wall invading lung with regional lymph node metastasis. Eur J Cardiothorac Surg; 2009 Jan;35(1):185-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He underwent initial resection of the left chest wall tumour with combined left lower lobectomy, left S5 segmentectomy, and lymph node dissection in order to facilitate a definitive diagnosis and also to obviate the risk of fatal bleeding due to tumour invasion of the pulmonary artery.
  • Diagnosis of peripheral primitive neuroectodermal tumour was confirmed.
  • After surgery, combination chemotherapy with cyclophosphamide, vincristine, doxorubicin, ifosphamide, and etoposide was given.
  • [MeSH-minor] Adult. Humans. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19036597.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


31. Escudero A, Flo A, Espí C, Moret E, Massó E, Cubells C: [Anesthesia in 2 cases of resection of a renal tumor involving the vena cava]. Rev Esp Anestesiol Reanim; 2006 Jun-Jul;53(6):378-82
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 1 case a portion reached the bifurcation of the pulmonary artery.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blood Loss, Surgical. Combined Modality Therapy. Dactinomycin / administration & dosage. Doxorubicin / administration & dosage. Extracorporeal Circulation. Fatal Outcome. Female. Hemostatic Techniques. Humans. Male. Middle Aged. Multiple Organ Failure / etiology. Neoplasm Invasiveness. Postoperative Hemorrhage / drug therapy. Pulmonary Embolism / etiology. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Blood Clots.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16910146.001).
  • [ISSN] 0034-9356
  • [Journal-full-title] Revista española de anestesiología y reanimación
  • [ISO-abbreviation] Rev Esp Anestesiol Reanim
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin
  •  go-up   go-down


32. Mansour Z, Kochetkova EA, Santelmo N, Ducrocq X, Quoix E, Wihlm JM, Massard G: Persistent N2 disease after induction therapy does not jeopardize early and medium term outcomes of pneumonectomy. Ann Thorac Surg; 2008 Jul;86(1):228-33
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent N2 disease after induction therapy does not jeopardize early and medium term outcomes of pneumonectomy.
  • BACKGROUND: Operative management of patients with persistent N2 disease after induction therapy is still debated.
  • METHODS: One hundred fifty-three consecutive patients underwent pneumonectomy from January 1999 until July 2005; 28 patients (18.3%) had persistent N2 disease after induction therapy (group 1), 32 patients (20.9%) had pathologic stage N0 or N1 after induction therapy (group 2), and 93 patients (60.8%) with pathologic N2 disease underwent immediate surgery (group 3).
  • RESULTS: Demographics of the three groups were similar (age, sex, side of operation, type of chemotherapy, smoking status, and comorbidity such as coronary artery disease, diabetes, and chronic obstructive pulmonary disease).
  • CONCLUSIONS: Our results suggest that pneumonectomy is justified in patients with persistent N2 disease after induction chemotherapy.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / therapy. Lung Neoplasms / pathology. Lung Neoplasms / therapy. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Cohort Studies. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Pneumonectomy / methods. Probability. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies. Risk Assessment. Statistics, Nonparametric. Survival Analysis. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2009 Mar;87(3):990-1 [19231456.001]
  • [CommentIn] Ann Thorac Surg. 2008 Jul;86(1):233-4 [18573429.001]
  • (PMID = 18573428.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


33. Hollaus PH, Wurnig PN, Pridun NS: [Bronchoplastic procedures for the resection of malignant bronchial neoplasms]. Chirurg; 2002 Nov;73(11):1115-22
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Bronchoplastic procedures have become established in the treatment of bronchial malignancies.
  • PATIENTS AND METHODS: Bronchial reconstruction techniques (wedge resection, end-to-end-anastomosis, y-sleeve), comorbidity (cardiovascular, respiratory, pulmonary, neoadjuvant chemotherapy, alcoholism), postoperative complications (septic/aseptic, light/severe), histology, tnm-stage and postoperative follow up (days) were recorded prospectively.
  • In 11 patients (10.2%), an additional angioplasty of the pulmonary artery was performed.
  • CONCLUSION: Bronchoplastic procedures are a safe method for the treatment of bronchial malignancies, even in cases with high comorbidity, and should be performed whenever possible.
  • [MeSH-minor] Adult. Aged. Anastomosis, Surgical. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Pneumonectomy. Postoperative Complications / etiology. Postoperative Complications / mortality. Risk Factors. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12430063.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


34. Hoffer FA: Interventional radiology in pediatric oncology. Eur J Radiol; 2005 Jan;53(1):3-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • I will discuss a number of interventions including percutaneous biopsy for solid tumor and hematological malignancy diagnosis or recurrence, for the diagnosis of graft versus host disease after stem cell or bone marrow transplantation, and for the diagnosis of complications of immunosuppression such as invasive pulmonary aspergillosis.
  • This is an alternative treatment for the local control of tumors that may not be amenable to surgery, chemotherapy or radiotherapy.
  • I will also describe how chemoembolization can be used to treat primary or metastatic tumors of the liver that have failed other therapies.
  • This treatment delivers chemotherapy in the hepatic artery infused with emboli to increase the dwell time and concentration of the agents.
  • [MeSH-major] Neoplasms / diagnosis. Radiology, Interventional
  • [MeSH-minor] Biopsy. Catheter Ablation. Chemoembolization, Therapeutic. Child. Humans. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / therapy

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15607848.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 54
  •  go-up   go-down


35. Kosaba S, Yamamoto K: [Carinal reconstruction with wide airway resection by a new technique]. Kyobu Geka; 2001 Jan;54(1):4-7
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 61-year man with tracheal stenosis by tracheal cancer, 6 tracheal rings, 2 left bronchial rings, total right main bronchus, for which carina was resected and reconstructed by a new technique and for a 69 year man with lung cancer in right upper lobe, for which right upper-middle bilobectomy, S6 segmental resection and circumferential pulmonary artery resection were performed.
  • The tracea, left main bronchus, and right basal segment bronchus were anastomosed by new technique and the right main pulmonary artery and basal segment artery was anastomosed subsequent to chemotherapy.
  • The new reconstructive method of carina permits simple anastomosis, the possibility of carina reconstruction even in the case of wide airway resection and loss tension at the site of anastomosis.
  • [MeSH-minor] Aged. Anastomosis, Surgical / methods. Humans. Lung Neoplasms / surgery. Male. Middle Aged. Neoplasm Invasiveness. Pneumonectomy. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11197908.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


36. Laurenzi L, Natoli S, Di Filippo F, Calamaro A, Centulio F, Anzà M, Cavaliere F, Marcelli ME, Garinei R, Arcuri E: Systemic and haemodynamic toxicity after isolated limb perfusion (ILP) with TNF-alpha. J Exp Clin Cancer Res; 2004 Jun;23(2):225-31
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Systemic and pulmonary haemodynamics, by a radial and pulmonary artery catheter inserted before the induction of anesthesia, were monitored at 5 different times: before the induction of anesthesia (T0), and 6, 12, 24 and 48 hours after treatment (T1-4).
  • These two patients had serious systemic toxicity: shock and respiratory failure secondary to pulmonary edema.
  • Acute pulmonary edema was also observed in another patient.
  • All three cases required supportive therapy provided by means of mechanical ventilation.
  • In three of the remaining 14 cases bilateral pulmonary leaks were noted, however the use of mechanical ventilation was not required.
  • [MeSH-major] Cardiovascular Diseases / chemically induced. Chemotherapy, Cancer, Regional Perfusion / adverse effects. Hemodynamics / drug effects. Melanoma / drug therapy. Respiratory Tract Diseases / chemically induced. Sarcoma / drug therapy. Tumor Necrosis Factor-alpha / adverse effects
  • [MeSH-minor] Adult. Aged. Extremities. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery. Postoperative Care. Prospective Studies. Skin Neoplasms / drug therapy. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15354406.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


37. Reijerkerk A, Mosnier LO, Kranenburg O, Bouma BN, Carmeliet P, Drixler T, Meijers JC, Voest EE, Gebbink MF: Amyloid endostatin induces endothelial cell detachment by stimulation of the plasminogen activation system. Mol Cancer Res; 2003 Jun;1(8):561-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We previously found that insoluble endostatin shows all the hallmarks of amyloid aggregates and potently stimulates tissue plasminogen activator-mediated formation of the serine protease plasmin.
  • [MeSH-major] Angiogenesis Inhibitors / pharmacology. Endostatins / pharmacology. Endothelium, Vascular / drug effects. Tissue Plasminogen Activator / metabolism
  • [MeSH-minor] Animals. Carboxypeptidase B / metabolism. Carboxypeptidase B / pharmacology. Cattle. Cells, Cultured. Colonic Neoplasms / blood supply. Colonic Neoplasms / drug therapy. Extracellular Matrix / drug effects. Extracellular Matrix / metabolism. Fibrinolysin / metabolism. Male. Mice. Mice, Inbred BALB C. Neoplasm Transplantation. Plasminogen / metabolism. Pulmonary Artery / cytology

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12805403.001).
  • [ISSN] 1541-7786
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Endostatins; 9001-91-6 / Plasminogen; EC 3.4.17.2 / Carboxypeptidase B; EC 3.4.21.68 / Tissue Plasminogen Activator; EC 3.4.21.7 / Fibrinolysin
  •  go-up   go-down


38. Hanna NN, Seetharam S, Mauceri HJ, Beckett MA, Jaskowiak NT, Salloum RM, Hari D, Dhanabal M, Ramchandran R, Kalluri R, Sukhatme VP, Kufe DW, Weichselbaum RR: Antitumor interaction of short-course endostatin and ionizing radiation. Cancer J; 2000 Sep-Oct;6(5):287-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mice bearing SQ-20B xenografts were injected intraperitoneally with 2.5 mg/kg/day of murine recombinant endostatin 5 times per week for 2 weeks 3 hours before IR treatment (50 Gy total dose).
  • Mice bearing Lewis lung carcinoma tumors were injected intraperitoneally with endostatin (2.5 mg/kg/day) four times; the first injection was given 24 hours before the first IR dose (15 Gy) and then 3 hours before IR (15 Gy/day) for 3 consecutive days.
  • Microvascular density was assessed on tumor tissue sections by use of CD31 immunohistochemistry and light microscopy.
  • RESULTS: In SQ-20B xenografts, combined treatment with endostatin and IR produced tumor growth inhibition that was most pronounced at the nadir of regression (day 21).
  • By day 35, tumors receiving combined treatment with endostatin and IR were 47% smaller than tumors treated with endostatin alone.
  • Interactive cytotoxic treatment effects between endostatin and IR were also demonstrated in mice bearing Lewis lung carcinoma tumors.
  • Histologic analyses demonstrated a reduction in microvascular density after combined treatment with endostatin and IR compared with endostatin treatment alone.
  • Combined treatment with endostatin and IR produced an increase in cow pulmonary artery endothelial apoptosis compared with either treatment alone.
  • DISCUSSION: The tumor regression observed after combined treatment with endostatin and IR suggests additive antitumor effects in both human and murine tumors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Collagen / therapeutic use. Neoplasms / drug therapy. Neoplasms / radiotherapy. Peptide Fragments / therapeutic use. Radiation, Ionizing
  • [MeSH-minor] Animals. Antigens, CD31 / biosynthesis. Apoptosis. Carcinoma, Lewis Lung / drug therapy. Cell Separation. Cells, Cultured. Cloning, Molecular. Collagen Type XVIII. Combined Modality Therapy. Dose-Response Relationship, Drug. Endostatins. Endothelium, Vascular / cytology. Endothelium, Vascular / drug effects. Escherichia coli / metabolism. Female. Flow Cytometry. Humans. Immunohistochemistry. Mice. Mice, Inbred C57BL. Microcirculation / drug effects. Microcirculation / radiation effects. Neoplasm Transplantation. Pichia / metabolism. Recombinant Proteins / metabolism. Time Factors. Tumor Cells, Cultured. Umbilical Veins / cytology. Umbilical Veins / drug effects

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11079167.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA81151; United States / NIDDK NIH HHS / DK / DK51711; United States / NIDCR NIH HHS / DE / P50DE/CA11921
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Antineoplastic Agents; 0 / Collagen Type XVIII; 0 / Endostatins; 0 / Peptide Fragments; 0 / Recombinant Proteins; 9007-34-5 / Collagen
  •  go-up   go-down






Advertisement